Each year, JAMA Internal Medicine publishes an update on overuse, featuring the top ten most influential articles on overuse from the previous year. Here are some highlights from this year's update! More
If you thought the only takeaway from ORBITA was "stents don't work," you're missing the point, says Dr. Vikas Saini in Health Affairs. More
If stents for stable angina don't work, what else doesn't work? As it turns out, arthroscopic surgery for shoulder pain... More
The ORBITA debate continues as the study authors respond to critical letters in The Lancet. More
Cancer advocacy groups are cheering the new screening guidelines for colorectal cancer, but few reports have examined both the costs and benefits of lowering the age of screening. More
Catheter ablation for atrial fibrillation has been used for 20 years, and grown into a $4.5 billion industry. But is the procedure actually effective? More
Are we oversimplifying the discussion when it comes to overuse? In a NEJM editorial, Lisa Rosenbaum argues that "less is more" can be a slippery slope. Here's what we thought about her controversial piece. More
Professor Doug McKell explains why ORBITA might not be enough to reduce unnecessary stents. More
Why was Gardasil originally marketed as a cervical cancer vaccine? Professor Samantha Gottlieb explains. More
Cardiologist David Brown addresses some of the criticisms of the controversial ORBITA trial. More
A study in The Lancet this week has rocked the world of cardiology by showing that stents are no better than a placebo in relieving chest pain. More
Why is clinical research such a mess? And how can we clean it up? More
How do we balance evidence and patient preferences in the intensifying statin debate? More
Rewarding doctors for following quality measures should be a win-win, but there's one problem- many of these measures don't actually make patients healthier. More